KAM
VRTX icon

Kazazian Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kazazian Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,512
Closed -$976K – 91
2017
Q4 		$976K Buy
6,512
+675
+12% +$99.9K 1% 24
2017
Q3 		$887K Buy
+5,837
New +$879K 1.09% 21

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kazazian Asset Management's VRTX Position: Q1 2018 in Review

Kazazian Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 6,512 shares — an estimated $976K sold.

Kazazian Asset Management first reported a position in VRTX in Q3 2017 and held it in 2 quarters. The position peaked at $976K in Q4 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • Kazazian Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 6,512 Vertex Pharmaceuticals shares in Q1 2018, an estimated $976K.
  • Kazazian Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Kazazian Asset Management's Vertex Pharmaceuticals position peaked at $976K in Q4 2017.
  • 680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on Kazazian Asset Management's 13F filing for Q1 2018, filed 15 May 2018.